Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) Cash & Equivalents: 2011-2023

Historic Cash & Equivalents for SELLAS Life Sciences Group (SLS) over the last 7 years, with Dec 2023 value amounting to $2.5 million.

  • SELLAS Life Sciences Group's Cash & Equivalents rose 425.77% to $21.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $21.0 million, marking a year-over-year increase of 425.77%. This contributed to the annual value of $2.5 million for FY2023, which is 85.23% down from last year.
  • According to the latest figures from FY2023, SELLAS Life Sciences Group's Cash & Equivalents is $2.5 million, which was down 85.23% from $17.1 million recorded in FY2022.
  • Over the past 5 years, SELLAS Life Sciences Group's Cash & Equivalents peaked at $35.3 million during FY2020, and registered a low of $2.5 million during FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $17.1 million (2022), whereas its average is $13.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 385.12% in 2020, then slumped by 85.23% in 2023.
  • Over the past 5 years, SELLAS Life Sciences Group's Cash & Equivalents (Yearly) stood at $7.3 million in 2019, then spiked by 385.12% to $35.3 million in 2020, then crashed by 39.51% to $21.4 million in 2021, then declined by 19.81% to $17.1 million in 2022, then crashed by 85.23% to $2.5 million in 2023.